8-K: Aptose Advances AML Trial to 160mg Dose

Aptose Biosciences' TUSCANY trial for AML advances to a 160 mg tuspetinib dose cohort after positive safety and efficacy data, securing additional funding.

Summary

• The Cohort Safety Review Committee (CSRC) approved escalating the tuspetinib (TUS) dose to 160 mg in Aptose's Phase 1/2 TUSCANY trial.
• The TUSCANY trial combines TUS with standard-of-care venetoclax (VEN) and azacitidine (AZA) for newly diagnosed Acute Myeloid Leukemia (AML) patients.
• Previous cohorts (40 mg, 80 mg, and 120 mg TUS doses) completed with no dose-limiting toxicities (DLTs) or significant safety concerns, including no prolonged myelosuppression in Cycle 1.
• The TUS+VEN+AZA triplet achieved complete remissions (CRs) and minimal residual disease (MRD)-negativity in difficult-to-treat AML populations, such as those with adverse biallelic TP53 or FLT3-ITD mutations, and those without FLT3 mutations.
• Aptose received an additional US$1.1 million advance from Hanmi Pharmaceutical Co. Ltd. under a US$8.5 million loan facility agreement.
• Total advances received under the loan agreement to date aggregate US$5.6 million.

Sentiment

Score: 8

Explanation: The filing reports significant positive progress in a key clinical trial, including successful dose escalation, excellent safety profile, and promising efficacy in difficult-to-treat patient populations. The additional funding also strengthens the company's financial position.

Positives

• Successful dose escalation to 160 mg TUS in the TUSCANY trial, indicating favorable safety and efficacy.
• Completion of 40 mg, 80 mg, and 120 mg TUS dose cohorts with no dose-limiting toxicities.
• No prolonged myelosuppression observed in Cycle 1 for subjects in remission.
• Achievement of complete remissions (CRs) and minimal residual disease (MRD)-negativity with the TUS+VEN+AZA triplet.
• Demonstrated efficacy in difficult-to-treat AML populations (e.g., adverse biallelic TP53 or FLT3-ITD mutations, and non-FLT3 mutations).
• No dose reductions required for standard-of-care VEN/AZA in combination with TUS.
• Secured an additional US$1.1 million advance from Hanmi Pharmaceutical, bringing total advances to US$5.6 million.

Risks

• Ability to obtain the capital required for research and operations and to continue as a going concern.
• Inherent risks in early-stage drug development, including demonstrating efficacy.
• Development time/cost and the regulatory approval process.
• Progress of clinical trials.
• Ability to find and enter into agreements with potential partners.
• Ability to attract and retain key personnel.
• Changing market conditions.
• Inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities.
• Unexpected manufacturing defects.

Future Outlook

The TUSCANY trial aims to create an improved, active, durable, and well-tolerated frontline therapy for newly diagnosed AML patients. Enrollment is open for the 160 mg TUS dose level, with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available.

Management Comments

• "In particular, patients with adverse biallelic TP53 or FLT3-ITD mutations, and those without FLT3 mutations, were able to safely achieve complete remissions with MRD negativity." Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose.
• "After review of the most recent safety and efficacy data, our CSRC recommended that we continue to escalate dosing." Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose.

Industry Context

The development of the TUS+VEN+AZA triplet therapy addresses a significant unmet medical need for newly diagnosed AML patients who are ineligible for induction chemotherapy, particularly those with difficult-to-treat mutations like TP53 or FLT3-ITD. This positions Aptose as a potential innovator in precision oncology, aiming for a mutation-agnostic frontline therapy.

Comparison to Industry Standards

• The TUS+VEN+AZA triplet is being developed as a "one-of-a-kind, safe and mutation agnostic frontline therapy" for newly diagnosed AML patients ineligible for induction chemotherapy.
• The trial uses "standard of care dosing of venetoclax and azacitidine" (VEN/AZA), indicating a combination approach with established treatments.
• The therapy has shown efficacy in "some of the most difficult-to-treat AML populations," including patients with adverse biallelic TP53 or FLT3-ITD mutations, and those without FLT3 mutations, which are typically challenging subgroups.
• Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations, including those with highly adverse TP53 and RAS mutations, and mutated or unmutated (wildtype) FLT3 genes, going beyond more prognostically favorable NPM1 and IDH mutant subgroups.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progress and funding could increase investor confidence and potentially share price.
• Patients: The development of a safe and effective frontline therapy for newly diagnosed AML, especially for difficult-to-treat populations, offers significant hope.
• Employees: Continued progress and funding provide job security and motivation.
• Creditors (Hanmi Pharmaceutical): The loan advances indicate a continued financial relationship and investment in Aptose's progress.

Next Steps

• Enrollment is open for dosing subjects at the 160 mg TUS dose level in the TUSCANY trial.
• Anticipated enrollment of 18-24 patients in the TUSCANY trial by late 2025.
• Data from the TUSCANY trial will be released as it becomes available.

Key Dates

Recommendation

The filing indicates strong positive clinical trial results for tuspetinib in AML, showing excellent safety and efficacy, including complete remissions in difficult-to-treat patient populations. Successful dose escalation and continued funding from a strategic partner de-risk the development pathway significantly. This progress suggests a high probability of future success and market potential for a "one-of-a-kind" therapy, making it an attractive investment.

Keywords

Aptose Biosciences, tuspetinib, AML, acute myeloid leukemia, TUSCANY trial, venetoclax, azacitidine, triplet therapy, oncology, clinical trial, Phase 1/2, precision medicine, Hanmi Pharmaceutical, drug development, biotechnology